Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Citation
Mann JFE, Hansen T, Idorn T, et al. Lancet Diabetes Endocrinol 2020; epub ahead of press.